Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Organovo Hol ...

Short interest in Organovo Holdings Inc (NASDAQ:ONVO) decreased during the last reporting period, falling from 78.04K to 71.89K. This put 0.48% of the company's publicly available shares short.

US equity indexes ended mixed on Tuesday, with an afternoon rebound carrying blue-chip stocks back to positive ground and paring earlier losses for other major market gauges after the Conference Board ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares ...

China needs to tackle its steel glut by cutting 15% of capacity this year, if mills are to meet their 2025 climate goals and ...

Eli Lilly (NYSE:LLY) announced plans to more than double its investments in domestic medicine production to over $50B on ...

Onvo Stock- Organovo's stock jumps 200% after Eli Lilly acquires its FXR program, including the promising IBD treatment ...

SAN DIEGO, CA, USA I5, 2025 I Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused ...